Verification evidence is still being completed.
PDF / print export
Verigraft
Gothenburg, Sweden
- Verified lead
- Petter Bjorkquist
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Regenerative Medicine, Tissue Engineering, Vascular Grafts, ATMPs, and Clinical Development
- Review cycle
- May 2026
- Full address
- Arvid Wallgrens Backe 20, 41346 Gothenburg, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official VERIGRAFT contact page confirming the Gothenburg address.
- Editorial note
- Verigraft is published because official company materials confirm current leadership, Gothenburg operating address, and a strong tissue-engineering and regenerative-medicine platform.
Regenerative Medicine, Tissue Engineering, Vascular Grafts, ATMPs, and Clinical Development
Official leadership disclosure, Official Gothenburg address disclosure, Clinical tissue-therapy platform claim
Verigraft is published because official company materials confirm current leadership, Gothenburg operating address, and a strong tissue-engineering and regenerative-medicine platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Gothenburg, Sweden
Verigraft
Regenerative Medicine, Tissue Engineering, Vascular Grafts, ATMPs, and Clinical Development · Clinical tissue-therapy platform
Verigraft runs tissue-engineered graft development, regenerative medicine programs, and clinical atmp development in Gothenburg, Sweden.
- Lead
- Petter Bjorkquist (verified ↗)
- Address
- Arvid Wallgrens Backe 20, 41346 Gothenburg, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 22 Mar 2026 (2mo ago)
- Scale
- Clinical tissue-therapy platform
- Capabilities
- Tissue-Engineered Graft Development · Regenerative Medicine Programs · Clinical ATMP Development
- Founded
- 2015
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Petter Bjorkquist
Chief Executive Officer
Full addressArvid Wallgrens Backe 20, 41346 Gothenburg, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Clinical tissue-therapy platform
Gothenburg, Sweden. Regenerative Medicine, Tissue Engineering, Vascular Grafts, ATMPs, and Clinical Development. Review completed on 22 Mar 2026.
Swedish corporate and advanced-therapy oversight
Official leadership disclosure, Official Gothenburg address disclosure, Clinical tissue-therapy platform claim
Regenerative Medicine, Tissue Engineering, Vascular Grafts, ATMPs, and Clinical Development
Verigraft is published because official company materials confirm current leadership, Gothenburg operating address, and a strong tissue-engineering and regenerative-medicine platform.
Editorial note
Verigraft is published because official company materials confirm current leadership, Gothenburg operating address, and a strong tissue-engineering and regenerative-medicine platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Tissue-Engineered Graft Development
Regenerative Medicine Programs
Clinical ATMP Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Tissue-engineering workflow
Regenerative medicine systems
Clinical development infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Verigraft located?
- Verigraft operates from Arvid Wallgrens Backe 20, 41346 Gothenburg, Sweden, Gothenburg, Sweden.
- Who runs Verigraft?
- Verigraft is led by Petter Bjorkquist, Chief Executive Officer. Verified 22 Mar 2026.
- What does Verigraft do?
- Verigraft runs tissue-engineered graft development, regenerative medicine programs, and clinical atmp development in Gothenburg, Sweden. Core capabilities: Tissue-Engineered Graft Development, Regenerative Medicine Programs, Clinical ATMP Development.
Editorial context
Related technical briefs
Briefs that name Gothenburg as a covered market or city.